Home Two New Post-Hoc Analyses of TRA 2°P TIMI 50 Study Showed ZONTIVITY (vorapaxar) Added to Aspirin and/or Clopidogrel Reduced Acute Limb Ischemia and Peripheral Revascularizations, Respectively, in Certain Patients with Peripheral Arterial Disease
 

Keywords :   


Two New Post-Hoc Analyses of TRA 2°P TIMI 50 Study Showed ZONTIVITY (vorapaxar) Added to Aspirin and/or Clopidogrel Reduced Acute Limb Ischemia and Peripheral Revascularizations, Respectively, in Certain Patients with Peripheral Arterial Disease

2015-03-05 14:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. These and other post-hoc subgroup analyses from TRA-2°P are being presented at the 2015 American College of Cardiology Scientific Sessions KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from two post-hoc analyses of the TRA 2°P TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events) trial of ZONTIVITY (vorapaxar), one of the largest secondary prevention studies of an antiplatelet medicine. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: with added study reduced

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
02.11Subtropical Storm Patty Update Statement
02.11Summary for Subtropical Storm Patty (AT2/AL172024)
02.11Atlantic Tropical Weather Outlook
02.11Eastern North Pacific Tropical Weather Outlook
02.11Weekly Recap: Nippon Paint, AkzoNobel, PPG Top This Weeks Stories
02.11Subtropical Storm Patty Graphics
02.11Subtropical Storm Patty Forecast Discussion Number 1
02.11Subtropical Storm Patty Wind Speed Probabilities Number 1
More »